Mounjaro, a recently approved medication, is generating considerable buzz within the glycemic care landscape. This twin-mechanism injectable treatment combines a GLP-1 receptor stimulator with a glucose-responsive insulinotropic polypeptide , offering a potentially impressive advancement in gluco